The convertible offering overhang and insider selling after a strong earnings beat suggest near-term downside pressure. Monitor the final pricing and conversion terms of the notes. The stock's strong quarter could provide a floor, but dilution risk may cap upside. Consider hedging against potential volatility through options strategies.
TVTX drugs
TVTX drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $44.12entry
- T+1 · 7mo ago +1.79%α +2.13% · $44.91
- T+5 · 6mo ago −3.31%α −5.66% · $42.66
- T+20 · 6mo ago +2.09%α −3.20% · $45.04
- T+60 · 4mo ago +26.72%α +23.65% · $55.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple Travere Therapeutics insiders, including the CEO, CFO, and CMO, sold shares in the days following strong Q1 2026 earnings and a $400M convertible note offering. Total open-market sales of $2.74M are tiny relative to the $4.1B market cap, but the clustering of sales by top executives after a dilutive capital raise raises governance concerns. The offering represents ~10% dilution, partially offset by robust revenue growth.
Key Financial Metrics
Key Facts
- CEO Eric Dube sold $989K worth of shares on May 6 at $43.95.
- CMO Jula Inrig sold $900K on May 4 and $101K on May 5, total $1.0M.
- Total insider open-market sales in the cluster: ~$2.74M (0.07% of market cap).
- Company filed a $400M convertible senior notes offering (424B5) on May 5, representing ~10% of market cap.
- Q1 2026 revenue surged 88% YoY to $124.5M, driven by FILSPARI sales; net loss narrowed to $37.1M from $41.2M.
- FDA approved FILSPARI for FSGS in April 2026, expanding addressable U.S. population to >100,000 patients.
Financial Impact
$400M convertible note offering (dilutive upon conversion); insider sales aggregated $2.74M
Risk Factors
- Dilution from $400M convertible notes; potential for share price to trade below conversion price.
- Insider selling pattern may signal lack of confidence at current valuation, despite strong operational results.
- Execution risk for FSGS launch and ongoing clinical trials (HARMONY study topline expected 2H 2027).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-TVTX-1778112057295 |
Track record
21 reports on TVTX
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
- Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
- Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
- Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
- Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers